Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ARC19499

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Aptamers, Nucleotide
BAX499

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.
BACKGROUND In recent years, a number of tissue factor pathway inhibitor (TFPI) antagonists have been developed to serve as… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2012
Highly Cited
2012
Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma
Summary.  Background:  Tissue factor pathway inhibitor (TFPI) is the major inhibitor of tissue factor‐initiated coagulation… Expand
2012
2012
Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.
INTRODUCTION In hemophilia, thrombin generation is significantly suppressed due to decreased factor (F)X activation. Clinical… Expand
2012
2012
Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.
INTRODUCTION Promoting thrombin generation by inhibiting tissue factor pathway inhibitor (TFPI) is a potentially viable… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Highly Cited
2011
Highly Cited
2011
Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
Hemophilia A and B are caused by deficiencies in coagulation factor VIII (FVIII) and factor IX, respectively, resulting in… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • figure 7
Highly Cited
2011
Highly Cited
2011
Improvement of spatial fibrin formation by the anti‐TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation
Summary.  Background: Tissue factor pathway inhibitor (TFPI) is a major regulator of clotting initiation and a promising target… Expand
2011
2011
Aptamer ARC 19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor
Hemophilia A and B are caused by deficiencies in coagulation factor VIII (FVIII) and factor IX, respectively, resulting in… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • figure 7
2010
2010
Inhibition of tissue factor pathway inhibitor (TFPI) by ARC19499 improves clotting of hemophiliac blood
Background Hemophilia A and B are disorders resulting from a deficiency in factor VIII (FVIII), and factor IX (FIX), respectively… Expand
2010
2010
TFPI Antagonist Aptamer ARC19499 Is a Procoagulant In Vitro and In Vivo.
Abstract 1134 Hemophilia is a bleeding disorder that results from deficiencies in coagulation factor VIII (FVIII; hemophilia A… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE